Search

Becton Dickinson and Co

Gesloten

SectorGezondheidszorg

183.41 0.86

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

180.71

Max

183.72

Belangrijke statistieken

By Trading Economics

Inkomsten

759M

449M

Verkoop

269M

5B

K/W

Sectorgemiddelde

30.601

57.002

EPS

3.23

Dividendrendement

2.37

Winstmarge

9.011

Werknemers

72,000

EBITDA

-23M

686M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+4.58% upside

Dividenden

By Acuity

Dividendrendement

Sectorgemiddelde

2.37%

2.22%

Volgende Winsten

5 nov 2026

Volgende dividenddatum

30 sep 2026

Volgende Ex Dividend datum

9 sep 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.3B

49B

Vorige openingsprijs

182.55

Vorige sluitingsprijs

183.41

Nieuwssentiment

By Acuity

21%

79%

67 / 340 Rangschikking in Healthcare

Becton Dickinson and Co Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 aug 2026, 19:36 UTC

Becton Dickinson is trading higher today, despite a reported decline in retail sales for July that raised concerns about consumer demand.

13 aug 2026, 22:01 UTC

Becton Dickinson shares are lower in after-market hours, continuing a decline from Thursday's close amid overall weakness in after-hours trading.

12 aug 2026, 23:46 UTC

Event

Becton Dickinson announced successful enrollment completion in the PREVENT clinical trial for Phasix™ Mesh. Shares remain roughly flat in after-market trading.

11 aug 2026, 22:26 UTC

Becton Dickinson is trading lower in after-market hours, reversing an initial gain. No specific news was identified to explain this price movement.

10 aug 2026, 19:43 UTC

News

Becton Dickinson reports EPS of $3.23, exceeding estimates, and updates fiscal 2026 guidance, driving shares higher amid strong health care equipment sector gains.

7 aug 2026, 21:11 UTC

News

Citigroup maintained its Buy rating on Becton Dickinson and raised its price target to $204, contributing to the stock's higher after-market trading.

6 aug 2026, 23:01 UTC

Becton Dickinson and Co shares are higher in after-market hours, continuing a trend of three consecutive daily gains and remaining above the 20-day moving average.

5 aug 2026, 19:46 UTC

Becton Dickinson shares are lower today amid broader market declines influenced by ADP's report on private sector job growth miss for July.

4 aug 2026, 23:16 UTC

Becton Dickinson shares higher in after-market trading, reflecting positive market sentiment amid falling crude oil prices and expectations of reduced inflationary pressures.

3 aug 2026, 22:51 UTC

Becton Dickinson shares are lower in after-market trading, influenced by a significant downturn in the Health Care Equipment sub-sector.

31 jul 2026, 19:46 UTC

Becton Dickinson is higher today, showing resilience amid rising bond yields and inflation concerns. The stock remains above its 20-day moving average.

30 jul 2026, 22:51 UTC

Becton Dickinson and Co shares are lower in after-hours trading, reflecting broader weakness in the Health Care Equipment sub-sector.

29 jul 2026, 23:56 UTC

Becton Dickinson and Co shares are higher in after-market hours, maintaining momentum from Wednesday's close amid uncertainty over future interest rate decisions.

28 jul 2026, 20:02 UTC

News

UBS initiated coverage of Becton Dickinson with a Buy rating and $190 price target, contributing to the stock's upward movement this week.

27 jul 2026, 20:06 UTC

Becton Dickinson shares are higher, reflecting strength near the upper end of their one-month range amid falling oil prices and declining Treasury yields.

24 jul 2026, 19:26 UTC

Becton Dickinson and Co is trading higher, supported by gains in the Health Care Equipment sub-sector and maintaining a position above its 20-day moving average.

23 jul 2026, 19:56 UTC

Becton Dickinson shares are lower, extending a five-session decline amid ongoing market concerns over corporate earnings and inflation pressures from rising oil prices.

21 jul 2026, 19:36 UTC

Becton Dickinson is trading lower today, extending a trend of three consecutive daily declines. No specific news was identified to explain the movement.

20 jul 2026, 20:14 UTC

Becton Dickinson remains roughly flat in after-market trading, positioned 1.12% above its 20-day moving average, but has declined for three consecutive sessions.

Peer Vergelijking

Prijswijziging

Becton Dickinson and Co Prognose

Koersdoel

By TipRanks

4.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 191.8 USD  4.58%

Hoogste 210 USD

Laagste 175 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Becton Dickinson and Co - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

5

Buy

5

Hold

0

Sell

Sentiment

By Acuity

67 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
help-icon Live chat